Ustinov V A, Matveeva V A, Kostyanko M A, Glushkov A N
Institute of Human Ecology of Siberian Branch of Russian Academy of Sciences, Kemerovo 650065, Russia.
Exp Oncol. 2013 Sep;35(3):207-10.
To evaluate the production of antibodies against benzo[a]pyrene (BP) (Ab1) and corresponding antiidiotypic antibodies (Ab2) in mice after immunization with BP-protein conjugate and in lung cancer patients.
The Ab1 and Ab2 levels were measured by non-competitive ELISA in blood serum of 10 mice immunized with BP-protein conjugate, and in blood serum of 288 healthy persons and 165 lung cancer patients.
The Ab1 level of was 2-fold higher than Ab2 level in blood serum of BP-immunized mice. In lung cancer patients the Ab1 level was almost 3 times higher and the Ab2 level was by 30% higher than these indexes in healthy individuals. The Ab1/Ab2 ratio was 2 in BP-immunized mice and healthy individuals and 1 in lung cancer patients.
Our data have shown that the Ab1/Ab2 ratio in lung cancer patients differ from that in healthy individuals and is close to the Ab1/Ab2 ratio in BP-immunized mouse.
评估用苯并[a]芘(BP)-蛋白偶联物免疫小鼠以及肺癌患者后,小鼠和肺癌患者体内抗苯并[a]芘抗体(Ab1)及相应抗独特型抗体(Ab2)的产生情况。
采用非竞争性酶联免疫吸附测定法(ELISA)检测10只用BP-蛋白偶联物免疫的小鼠血清、288名健康人和165名肺癌患者血清中的Ab1和Ab2水平。
BP免疫小鼠血清中Ab1水平比Ab2水平高2倍。肺癌患者血清中Ab1水平几乎比健康个体高3倍,Ab2水平比健康个体高30%。BP免疫小鼠和健康个体的Ab1/Ab2比值为2,肺癌患者的该比值为1。
我们的数据表明,肺癌患者的Ab1/Ab2比值与健康个体不同,且接近BP免疫小鼠的Ab1/Ab2比值。